STOCK TITAN

Relmada Therapeutics Inc - RLMD STOCK NEWS

Welcome to our dedicated news page for Relmada Therapeutics (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Relmada Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Relmada Therapeutics's position in the market.

Rhea-AI Summary
Relmada Therapeutics announces dosing of first patient in Phase 3 trial for REL-1017 as adjunctive treatment of MDD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.94%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.16%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences earnings
Relmada Therapeutics Inc

Nasdaq:RLMD

RLMD Rankings

RLMD Stock Data

140.31M
25.61M
8.24%
46.28%
5.62%
Sporting and Athletic Goods Manufacturing
Manufacturing
Link
US
New York

About RLMD

relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and